Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 153-159

  Aldape, Michael John ^a   Heeney, Dustin Delaney ^a   Bryant, Amy Evelyn ^a,b   Stevens, Dennis Leroy ^a,b  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Human disease; Infectious diseases; Pathogenic bacteria

Indexed keywords

BACTERIAL TOXIN; MESSENGER RNA; METRONIDAZOLE; TIGECYCLINE; TOXIN A; TOXIN B; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; ENTEROTOXIN; MINOCYCLINE; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ARTICLE; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COLONY FORMING UNIT; GENE EXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PEPTOCLOSTRIDIUM DIFFICILE; RESTRICTION MAPPING; SPOROGENESIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; ENTEROTOXINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SPORES, BACTERIAL;

EID: 84922163201     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku325     Document Type: Article

References (24)

1. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-80.
2. Carter GP, Douce GR, Govind R et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog 2011; 7: e1002317.
3. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136: 1913-24.
4. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15: 573-81.
5. Shah D, Dang MD, Hasbun R et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8: 555-64.
6. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 2011; 45: 1005-10.
7. Lao D, Chiang T, Gomez E. Refractory Clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep Med 2012; 2012: 702910.
8. Herpers BL, Vlaminckx B, Burkhardt O et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 1732-5.
9. Drummond LJ, Smith DG, Poxton IR. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile. J Med Microbiol 2003; 52: 1033-8.
10. Gerber M, Walch C, Loffler B et al. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol 2008; 57: 776-83.
11. Aldape MJ, Packham AE, Nute DW et al. The effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol 2013; 62: 741-7.
12. Moore P, Kyne L, Martin AJ et al. Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J Med Microbiol 2013; 62: 1405-13.
13. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Seventh Informational Supplement M11-A7. CLSI, Wayne, PA, USA, 2007.
14. Merrigan M, Venugopal A, Mallozzi M et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010; 192: 4904-11.
15. Lawley TD, Croucher NJ, Yu L et al. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol 2009; 191: 5377-86.
16. Noren T, Alriksson I, Akerlund T et al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010; 16: 1104-10.
17. Akerlund T, Persson I, Unemo M et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 2008; 46: 1530-3.
18. Lu CL, Liu CY, Liao CH et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010; 35: 311-2.
19. Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011; 194: 374-5.
20. Kopterides P, Papageorgiou C, Antoniadou A et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010; 38: 755-8.
21. Hoffmann M, DeMaio W, Jordan RA et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007; 35: 1543-53.
22. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375-80.
23. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes inmethicillin-sensitive andmethicillinresistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-11.
24. Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014; 14: 29.